These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 1486673)

  • 1. Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.
    Ginsberg GM; Berger S; Shouval D
    Bull World Health Organ; 1992; 70(6):757-67. PubMed ID: 1486673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.
    Ginsberg GM; Shouval D
    J Epidemiol Community Health; 1992 Dec; 46(6):587-94. PubMed ID: 1494073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
    Griffiths UK; Hutton G; Das Dores Pascoal E
    Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity.
    Ginsber GM; Slater PE; Shouval D
    J Hepatol; 2001 Jan; 34(1):92-9. PubMed ID: 11211913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-benefit analysis of vaccinal prevention of hepatitis B policy].
    Kerleau M; Flori YA; Nalpas B; Lanoé JL; Berthelot P; Fardeau-Gautier M
    Rev Epidemiol Sante Publique; 1995; 43(1):48-60. PubMed ID: 7892516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on the cost-effectiveness, benefit and utility analysis on the infant inoculation hepatitis B vaccine in Shanghai].
    Wu GY; Gong YL; Yu SL; Shao RT; Qin HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):474-8. PubMed ID: 15231120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
    Vimolket T; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China].
    Zhang SX; Dang RB; Zhang WD; Liang XF; Cui FQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Oct; 29(10):1003-8. PubMed ID: 19173882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The use of decision making analysis for evaluating hepatitis B inoculation strategy].
    Zhuang GH; Xu HW
    Zhonghua Yu Fang Yi Xue Za Zhi; 1993 Mar; 27(2):69-73. PubMed ID: 8354107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of hepatitis B screening in a mental health institution.
    Leonard J; Holtgrave DR; Johnson RP
    J Fam Pract; 1991 Jan; 32(1):45-8. PubMed ID: 1824638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-benefit analysis on immunization of newborns with hepatitis B vaccine in Jinan City].
    Liu ZG; Zhao SL; Zhang YX
    Zhonghua Liu Xing Bing Xue Za Zhi; 1995 Apr; 16(2):81-4. PubMed ID: 7781052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chinese strategies for hepatitis B virus markers screening in hepatitis B vaccination based on cost-effectiveness analysis].
    Zhang SX
    Zhonghua Yu Fang Yi Xue Za Zhi; 1992 May; 26(3):154-8. PubMed ID: 1395956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-benefit analysis of hepatitis B vaccination.
    Jönsson B
    Postgrad Med J; 1987; 63 Suppl 2():27-32. PubMed ID: 3120169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries.
    Das A
    Hepatology; 1999 Feb; 29(2):548-52. PubMed ID: 9918934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of running a universal adolescent hepatitis B vaccination programme.
    Wallace LA; Young D; Brown A; Cameron JC; Ahmed S; Duff R; Carman WF; Kitchin NR; Nguyen-Van-Tam JS; Goldberg DJ
    Vaccine; 2005 Dec; 23(48-49):5624-31. PubMed ID: 16099079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.
    Oddone EZ; Cowper PA; Hamilton JD; Feussner JR
    Health Serv Res; 1993 Apr; 28(1):97-121. PubMed ID: 8463111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Forecasting strategies of hepatitis B vaccination based on decision tree model].
    Zhang SX
    Zhonghua Liu Xing Bing Xue Za Zhi; 1989 Aug; 10(4):193-7. PubMed ID: 2509074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness and cost benefit of viral hepatitis B vaccination in the Slovak Republic.
    Hudecková H; Straka S; Szilágyiová M; Avdicová M; Rusnáková S
    Cent Eur J Public Health; 2002 Dec; 10(4):146-8. PubMed ID: 12528387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.